At Merck, Business Development As Usual?

Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.

By Ellen Foster Licking

The mega-marriages of 2009 between Pfizer Inc. and Wyeth and Merck & Co. Inc. and Schering-Plough Corp. created...

More from Business Strategy

More from In Vivo